High quality on sale Weight Loss Peptide GLP-1 Retatrutide 99% Purity Peptides 10mg

You can contact me at any time~

Name:Mary

Whatsapp:+86 152 2772 7503

Email Address:sales1@xttch.com

Retatrutide is a novel multi-target GLP-1 (glucagon-like peptide-1) receptor agonist that can also activate GIP (glucose-dependent otropic polypeptide) and glucagon receptors. It is currently mainly in the clinical trial stage and has attracted widespread attention for its potential in the treatment of obesity and type 2 diabetes.

1. Mechanism of Action

Retaglutide is a "triple agonist" that works by simultaneously targeting three metabolism-related receptors:

GLP-1 receptor: promotes secretion, inhibits glucagon release, and delays gastric emptying, thereby lowering blood sugar and producing a sense of fullness.

GIP receptor: enhances sensitivity and may work synergistically with GLP-1 receptor to further improve glucose metabolism.

Glucagon receptor: when moderately activated, it can increase energy consumption (such as promoting fat decomposition), which may make it more advantageous than a single GLP-1 receptor agonist (such as semaglutide) in weight loss.

This multi-target mechanism of action enables it to regulate blood sugar and achieve weight loss by suppressing appetite and increasing energy consumption.

II. Clinical Research Progress

Currently, clinical trials of retaglutide are mainly focused on obesity and type 2 diabetes. Preliminary results show significant weight loss and glucose control effects:

Weight loss effect: In a Phase II clinical trial for obese patients (without diabetes), retaglutide (maximum dose 12 mg) was injected once a week for 48 weeks, and the average weight loss of patients was about 24%, which is much higher than similar drugs (such as semaglutide, which lost about 15%-20% in similar trials).

Glycemic-lowering effect: Studies on patients with type 2 diabetes have shown that it can significantly reduce glycated hemoglobin (HbA1c) levels and improve resistance.

Safety: Common adverse reactions are similar to other GLP-1 drugs, including gastrointestinal reactions such as nausea, vomiting, and diarrhea. Most of them are mild to moderate and can be gradually relieved as treatment progresses; but long-term safety still needs to be verified by larger-scale Phase III clinical trials.

3. Potential advantages

Compared with existing single-target or dual-target drugs (such as GLP-1/GIP), the potential advantages of retaglutide include:

Stronger weight loss effect: Triple receptor activation may regulate energy balance more efficiently, especially for patients with severe obesity.

Multi-metabolism improvement: There may be comprehensive benefits in terms of sugar control and improvement of blood lipids (such as lowering triglycerides).

Convenience of administration: In the current study, it is subcutaneously injected once a week, and patient compliance is high.

Changsha Duole Technology Co., Ltd was established in 2020 with strong research and development capabilities and superb synthesis technology, as well as advanced quality control measures.

With synthetic biology platform technology as the core, it conducts innovative research and development, mainly engaged in the research and development of recombinantly expressed pharmaceutical peptides and proteins. Its products include innovative drugs, APIs, pharmaceutical and green synthetic industrial enzymes, functional peptides and protein products, etc.

Its core team is composed of technical experts in the fields of pharmaceutical engineering, fermentation engineering and protein engineering. The company has built a 3,300-square-meter recombinant drug research and development center in Shibei, Yuelu District, Changsha City. It has a complete pharmaceutical engineering, preparation and quality research system and talent team, and has built a GMP workshop to meet the international market API supply and CDMO services.

At present, our company has realized the industrialization of a variety of biosynthetic peptide products and has obtained cooperation orders from many well-known domestic and foreign pharmaceutical companies.